Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 479 Carcinoma, Non-Small-Cell Lung 436 Prostatic Neoplasms 277 Lung Neoplasms 169 Stomach Neoplasms 138 Neoplasms 112 Squamous Cell Carcinoma of Head and Neck 109 Head and Neck Neoplasms 97 Neoplasm Metastasis 93 Esophageal Neoplasms 70 Ovarian Neoplasms 56 Pancreatic Neoplasms 41 Sarcoma 39 Urinary Bladder Neoplasms 38 Nasopharyngeal Carcinoma 32 Carcinoma, Squamous Cell 30 Triple Negative Breast Neoplasms 28 Carcinoma, Ovarian Epithelial 28 Adenocarcinoma of Lung 27 Adenocarcinoma 27 Esophageal Squamous Cell Carcinoma 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Carcinoma, Transitional Cell 23 Adenocarcinoma Of Esophagus 23 Breast Neoplasms, Male 22 Recurrence 21 Unspecified Adult Solid Tumor, Protocol Specific 20 Inflammatory Breast Neoplasms 20 Fallopian Tube Neoplasms 20 Melanoma 18

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × Docetaxel × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡